Another study by Ferrara et al. concluded that circulating T cell senescence correlates with progression, HPD, and poor survival upon ICB in advanced NSCLC patients treated with single agent PD-1/PD-L1 inhibitors, as determined by assessing the percentage of a senescent immune phenotype (CD28−CD57+KLRG1+) in circulating CD8+ T cells [112]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.